Replies to post #158387 on NorthWest Biotherapeutics Inc (NWBO)

[Omayr]

Too optimistic? The question is “IF” it works and we dont know “IF” it really works so thinking about $100/sh as of now is insane.
GL

[anders2211]

So what you are saying is that NWBO will have a 100 billion market cap after Direct is approved? So about 20 billion bigger than lets say Bayer?

Keep on dreaming :)

[jondoeuk]

Other intratumoral therapies in trials include TLR/STING/RIG-I/NLRP3 agonists and oncolytic viruses. Data from some of these has shown durable responses (ORR & DCR) under certain criteria (WHO, RECIST or irRC).

IMO-2125 (a TLR9 agonist) by $IDRA will be going into a PhIII for PD-1 R/R melanoma patients this year. They also have some early data from a basket trial http://ir.iderapharma.com/static-files/e4c4cb99-9f35-4f8e-ba4b-74fc17e1faea

Then there is G100 (a TLR4 agonist) by $IMDZ which is likely going into a pivotal trial in certain patients with follicular lymphoma http://www.immunedesign.com/wp-content/uploads/2017/12/Intratumoral-G100-Poster-10Dec17_Final.pdf http://www.immunedesign.com/wp-content/uploads/2017/06/ASCO-2017-G100-Monotherapy-NHL-Dose-Esc-Final-Reduced-Size.pdf